Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
http://www.meetup.com/Berkeley-Biolabs/events/141420912/
Clive Holmes, et al.
Summary: Background Immunisation of patients with Alzheimer's disease with full-length amyloid-β peptide (Aβ42) can clear amyloid plaques from the brain. Our aim was to assess the relation between Aβ42 immune response, degree of plaque removal, and long-term clinical outcomes.
One claim made in the paper is that patients "with virtually complete plaque removal, had severe end stage dementia." John would like us to discuss this claim, and determine if really supported by the data. If yes, how? If not, what else might the data mean?
Look forward to a wonderful discussion. Please make sure to make a zoom.us account to join the discussion.
Tel: (415) 825 2705
-- You received this message because you are subscribed to the Google Groups DIYbio group. To post to this group, send email to diybio@googlegroups.com. To unsubscribe from this group, send email to diybio+unsubscribe@googlegroups.com. For more options, visit this group at https://groups.google.com/d/forum/diybio?hl=en
Learn more at www.diybio.org
---
You received this message because you are subscribed to the Google Groups "DIYbio" group.
To unsubscribe from this group and stop receiving emails from it, send an email to diybio+unsubscribe@googlegroups.com.
To post to this group, send email to diybio@googlegroups.com.
Visit this group at http://groups.google.com/group/diybio.
To view this discussion on the web visit https://groups.google.com/d/msgid/diybio/CABsHAf2ZkhdJKrXrR2oMySFCyOzByOPjJ2WEaLxA5VEm1gm%2Bvw%40mail.gmail.com.
For more options, visit https://groups.google.com/groups/opt_out.
0 comments:
Post a Comment